Neurocrine Biosciences Revenue increased by 1.1% to $814.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.2%, from $572.60M to $814.50M. Over 4 years (FY 2021 to FY 2025), Revenue shows an upward trend with a 26.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Growth indicates successful market penetration, pricing power, or volume expansion, while a decline suggests weakening demand or competitive pressure.
This represents the total gross revenue generated from the sale of goods and services to customers, excluding any sales-...
The standard top-line revenue metric used across all public companies for financial reporting.
other_revenue_from_contract_with_customer_excluding_asse_0d5b70| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $288.90M | $296.00M | $312.00M | $310.60M | $378.20M | $387.90M | $412.00M | $420.40M | $452.70M | $498.80M | $515.20M | $515.30M | $590.20M | $622.10M | $627.70M | $572.60M | $687.50M | $794.90M | $805.50M | $814.50M |
| QoQ Change | — | +2.5% | +5.4% | -0.4% | +21.8% | +2.6% | +6.2% | +2.0% | +7.7% | +10.2% | +3.3% | +0.0% | +14.5% | +5.4% | +0.9% | -8.8% | +20.1% | +15.6% | +1.3% | +1.1% |
| YoY Change | — | — | — | — | +30.9% | +31.0% | +32.1% | +35.4% | +19.7% | +28.6% | +25.0% | +22.6% | +30.4% | +24.7% | +21.8% | +11.1% | +16.5% | +27.8% | +28.3% | +42.2% |